Sunday 18 October 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.00
0.14
−4.46%
Follow EYPT
EyePoint, Inc. (EYPT) P/E ratio
EyePoint, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 21.5× (December 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 38 more quarters | Free account |
Against its own ten years
Low 0.0×
High 21.5×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABEO Abeona Therapeutics Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| EYPT EyePoint, Inc. | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| PALI Palisade Bio, Inc. compare | 2.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)